Quite true. If Vascepa was unique in terms of cardiovascular risk reduction, then it would be a different story. There would be a compelling need. Managed care would cover without question. However, there are other meds that present similar outcomes. Perhaps not as good, yet just enough for some managed care plans to act this way
News 
Market Data 
Discover 
AI
